# Regimen for Thoracic Oncology (2024)

## Table of contents
### NSCLC
* Neoadjuvant
* Nivolumab + AP (Pemetrexed/Cisplatin)
* Nivolumab + AP (Pemetrexed/Cisplatin)
* Nivolumab + GP (Gemcitabine/Cisplatin)
* Nivolumab + TC (Paclitaxel/Carboplatin)
* GP (Neoadjuvant)
* Pembrolizumab + AP (Pemetrexed/Cisplatin)
* Pembrolizumab + GP (Gemcitabine/Cisplatin)
* Durvalumab + AP (Pemetrexed/Cisplatin)
* Durvalumab + GP (Gemcitabine/Cisplatin)

### Adjuvant
* NP (Vinorelbine/Cisplatin)
* AP (Pemetrexed/Cisplatin)
* AC (Pemetrexed/Carboplatin)
* TC (Paclitaxel/Carboplatin)
* Atezolizumab (허가만족, PD-L1(SP263)≥50%)
* Pembrolizumab (허가만족, PD-L1 all comer)

### CCRT & Consolidation
* CCRT with weekly TC
* Durvalumab (Consolidation)

### Palliative
* Pembrolizumab+Pemetrexed+Carboplatin (1st line)
* Pembrolizumab+Pemetrexed+Cisplatin (1st line)
* Pembrolizumab+Paclitaxel+Carboplatin (1st line)
* 
* Pembrolizumab (1st line)
* Pembrolizumab (≥2nd line)
* Nivolumab (≥2nd line, q 2 weeks)
* Atezolizumab (≥2nd line)
